PowerShares Dynamic Pharmaceuticals ETF
An Easier Way to Understand the Pharma Industry
In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
How Bausch Health’s Financials Look in November
Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.
A Look at Merck’s Diabetes and Women’s Health Business
Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline.
A Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.
How Did Pharmaceutical ETFs Perform in Q3 2018?
The Healthcare Select Sector SPDR ETF’s (XLV) price has increased ~14.6% in the third quarter, and its year-to-date returns increased ~15.5% on October 2.
What’s Eli Lilly’s Valuation as of September 27?
Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue.
Comparing Pfizer Stock and Merck and Co. Stock
Merck & Co. (MRK) stock has risen ~3.2% in the same period, with a closing price of $70.78 on September 24.
Allergan’s SpotLyte and Lumivive System
SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.
A Look at the Dividends Paid by Pharma Stocks in 2018
In this article, we’ll discuss the details of the dividends paid by the pharmaceutical stocks under review in this series.
Allergan’s US Specialized Therapeutics Segment in Q2 2018
Allergan’s US Specialized Therapeutics segment reported revenue of $1.83 billion in the second quarter.
Examining Pfizer’s Performance by Geography in Q2 2018
Pfizer (PFE) reported a rise in revenue in international markets during the second quarter. Lower sales from its US markets offset this rise.
Analysts’ Targets and Recommendations for Amgen Stock
Amgen (AMGN) stock has risen 6.2% over the last 12 months, and ~9.5% year-to-date.
How Allergan Stock Performed in June
Leading pharmaceutical company Allergan (AGN), which deals in generic and specialty pharmaceutical products, segregated its business into three segments: US General Medicines, US Specialized Therapeutics, and International.
Eli Lilly’s Q1 2018 Top Line Rose 9% to $5.7 Billion
Eli Lilly’s net adjusted income increased to ~$1.4 billion during Q1 2018, compared to net adjusted income of $1.0 billion during Q1 2017.
Pfizer’s Performance across Geographies
As discussed earlier, Pfizer’s (PFE) international revenue grew in Q1 2018, while its US sales fell.
Analysts’ Recommendations for Eli Lilly in March 2018
Eli Lilly’s stock price has fallen nearly 11.2% in the last 12 months and nearly 11.5% in 2018 year-to-date.
A Look at Bristol-Myers Squibb’s Eliquis in 4Q17
Eliquis is one of Bristol-Myers Squibb’s (BMY) top-selling cardiovascular drugs.
How Pfizer Performed across Geographies during 4Q17
Pfizer reported revenue of ~$6.5 billion in US markets during 4Q17, a 4% fall compared to ~$6.8 billion in 4Q16.
President Trump’s State of the Union Speech Is Market Positive
In his first State of the Union speech, President Trump didn’t have any surprises for the markets. Financial markets were anxious before the speech.
Vermont Legalizes Recreational Marijuana on January 22, 2018
On January 22, Vermont decriminalized the possession of marijuana for adults 21 and older. Vermont became the ninth state to legalize marijuana for recreational purposes.
A Look into Amgen’s Collaborations in 2H17
Products under the Kirin–Amgen joint venture include Epogen, Neulasta, Aranesp, Nplate, and Neupogen.
Behind Valeant’s Branded Drugs: Other 3Q17 Performances
In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.
How Analysts Rated Jazz Pharmaceuticals in December
In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.
Johnson & Johnson’s Profit Margins in 3Q17
Johnson & Johnson’s (JNJ) gross profit margin decreased to 64.9% during 3Q17, a decline of ~4.0% compared to the gross profit margin of 69.2% during 3Q16.
Eli Lilly’s Revenue Trend in 3Q17
US markets contributed 55% of Eli Lilly’s total revenues in 3Q17. US sales rose 9% to $3.1 billion in 3Q17 compared to 3Q16.
How Did Invokana Perform in 3Q17?
Invokanna reported year-to-date (or YTD) September 2017 revenues of $844 million compared to $1.0 billion in YTD (year-to-date) September 2016.
How Bristol-Myers Squibb’s Oncology Portfolio Performed in 3Q17
The oncology portfolio Bristol-Myers Squibb’s (BMY) oncology portfolio includes key products Empliciti, Opdivo, Sprycel, and Yervoy. The oncology portfolio contributes over 40% of Bristol-Myers Squibb’s total revenue. Empliciti The above chart compares key oncology products’ revenue over the last few quarters. Empliciti is the latest drug launched by Bristol-Myers Squibb for the treatment of multiple myeloma. […]
Valeant Pharmaceuticals’ Siliq Approved for Plaque Psoriasis
In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals’ (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.
Keytruda: Driving Merck’s Growth
For 3Q17, Keytruda reported revenues of ~$1.1 billion, a 194% growth compared to revenues of $356 million in 3Q16.
How Pfizer’s Premarin and Other Legacy Established Products Performed
In 3Q17, Pfizer’s (PFE) Premarin generated revenues of $238 million, a ~2% decline on a YoY basis and a 3% decline on a quarter-over-quarter basis.
Behind Eli Lilly’s Alimta and Other Oncology Products in 3Q17
In 3Q17, Eli Lilly’s overall revenues from oncology products fell due to lower sales of Alimta, Erbitux, and Portrazza, offset by a rise in Cyramza sales.
How Merck’s Hospital Acute Care Portfolio Performed in 3Q17
Bridion revenue In 3Q17, Merck’s (MRK) Bridion reported revenue of $185 million, which reflected ~33% growth YoY (year-over-year) and 13% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Bridion generated revenue of $495 million, which reflected 44% growth YoY. Growth in US sales volumes primarily contributed to the drug’s revenue growth in the two […]
Merck’s Immunology and Oncology Drugs, Post-3Q17
Immunology drug revenue In 3Q17, Remicade generated revenue of $214 million, a ~31% fall YoY (year-over-year) and 3% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Remicade reported revenue of $651 million, which reflected a ~35% fall YoY. Foreign exchange had a 3% favorable effect towards 3Q17 Remicade revenue. In 3Q17, Simponi reported revenue of […]
What Led to the Rise in the US Trade Deficit in September?
The latest report was released on November 3 and indicated that the goods and services deficit was $43.5 billion in September, or $0.7 billion higher than in August.
Inside Pfizer’s Product Developments in 3Q17
In October 2017, the FDA approved Pfizer’s Lyrica CR (pregabalin), a once-daily extended-release tablet for the management of postherpatic neuralgia.
Valeant Pharmaceuticals’ U.S. Diversified Products Franchise
In 1H17, Valeant Pharmaceuticals International’s (VRX) U.S. Diversified Products franchise reported revenues of $519.0 million compared to $848.0 million in 1H17.
US Pharma Mergers and Acquisitions in 3Q17
Calendar 3Q17 saw several major mergers and acquisitions in the US pharmaceutical industry.
Bristol-Myers Squibb’s Cardiovascular Portfolio
Bristol-Myers Squibb’s (BMY) cardiovascular portfolio includes the blockbuster drug Eliquis, developed in alliance with Pfizer (PFE).
How Are Johnson & Johnson’s Revenues Trending?
Johnson & Johnson (JNJ) reported revenues of $18.8 billion in 2Q17, a 2% increase as compared to revenues of $18.5 billion in 2Q16.
How Merck’s Diabetes Portfolio Performed in 2Q17
Merck’s (MRK) diabetes portfolio includes drugs used for controlling the blood sugar levels for patients with diabetes.
Why Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018
In August 2017, JAZZ’s Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.
Eli Lilly & Co.’s Recent Developments after Its 2Q17 Earnings
On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.
Performance of Eli Lilly’s Endocrine Franchise in 2Q17
Forteo is used for the treatment of osteoporosis. Forteo’s sales totaled $446.7 million during 2Q17, a 22.0% increase compared to $367.6 million in 2Q16.
Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders
Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.
How Pfizer’s Enbrel and Xeljanz Are Positioned after 2Q17
In August 2017, the Arthritis Advisory Committee of the FDA recommended a positive opinion for the proposed dose of Xeljanz for the treatment of individuals with active psoriatic arthritis.
A Post-2Q17 Look at Pfizer’s Internal Medicines
In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.
Bristol-Myers Squibb’s Immunoscience Products in 2Q17
Orencia revenues rose to $650.0 million in 2Q17, a 10.0% rise compared to $593 million in 2Q16.
A Look into Merck’s Immunology and Oncology Portfolio
In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.
What Jazz Pharmaceuticals Expects for Vyxeos
If Vyxeos manages to penetrate a sizeable portion of the target market, it may have a favorable impact on Jazz Pharmaceuticals stock.
How Allergan’s US Specialized Therapeutics Segment Performed in 2Q17
The US Specialized Therapeutics segment reported revenues of $1.7 billion in 2Q17, a 15.2% increase as compared to $1.5 billion during 2Q16.
Behind Xyrem’s Solid Demand Trends in 2017
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem reported revenues of ~$298 million, which represented a YoY (year-over-year) growth of ~6% and sequential growth of ~9%.
Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17
In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.
How Amgen’s Nephrology Drugs Are Positioned after 2Q17?
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.
Celgene’s Abraxane Continued Steady Growth in 2Q17
In 2Q17, Celgene’s (CELG) Abraxane generated revenues of around $254 million, which reflected ~2% growth on a year-over-year basis.
Examining Bristol-Myers Squibb’s Oncology Portfolio’s 2Q17
The key products in Bristol-Myers Squibb’s (BMY) oncology portfolio include Empliciti, Opdivo, Sprycel, and Yervoy. Let’s take a closer look at these drugs and their performances.
Dupixent Could Substantially Drive Regeneron’s Growth
In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.
Eli Lilly in 2Q17: Humulin and Endocrine Products
Eli Lilly’’s (LLY) Human Pharmaceuticals segment reported a rise of ~11.0% to ~$5.0 billion for 2Q17 compared to ~$4.6 billion for 2Q16.
Behind Pfizer’s Legacy Established Products Performance in 2017
In 2016, Pfizer’s (PFE) Lipitor reported revenues of ~$1.8 billion, which represented a ~5% YoY (year-over-year) fall.
Behind Allergan’s Business Segments and Revenues
Allergan’s (AGN) business has undergone several changes over the past few years due to acquisitions and divestitures.
How Bristol-Myers Squibb Stock Has Performed in 2Q17
A look at Bristol-Myers Squibb Headquartered in New York City, Bristol-Myers Squibb (BMY) is an American pharmaceutical company that develops innovative medicines in various therapeutic areas, including cardiovascular, neuroscience, immunoscience, oncology, and virology. Stock price performance While Bristol-Myers Squibb’s stock price has risen ~3.8% in 2Q17, it had fallen ~5.4% year-to-date as of July 7, […]
How Did Keytruda Perform in 1Q17?
Merck (MRK) launched Keytruda in 4Q14 and reported global sales of $584 million for 1Q17. As a result, the company reported ~134% growth in revenues compared to $249 million in 1Q16.
A Look at Pfizer’s Revenue for 1Q17
Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.
How Johnson & Johnson’s Valuation Changed Post-1Q17
Heavyweight pharmaceutical company Johnson & Johnson (JNJ) reported earnings per share (or EPS) of $1.83 on revenue of $17.8 billion in 1Q17.
Performance of Merck’s Diabetes Portfolio in 1Q17
Combined sales for Januvia and Janumet were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16.
Understanding Allergan’s Valuation after the 1Q17 Results
On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.
Bristol-Myers Squibb’s 1Q17 Estimates: Virology Segment
The Virology segment is Bristol-Myers Squibb’s (BMY) second-largest revenue contributor. The segment contributes ~25% of the company’s total revenue.
Johnson & Johnson’s 1Q17 Segment-by-Segment Performance
JNJ’s overall business is classified into three segments: Pharmaceuticals, Consumer, and Medical Devices. At constant exchange rates, the company reported growth across all of its segments.
Johnson & Johnson’s 1Q17 Estimates: Pharmaceuticals Segment
Johnson & Johnson’s (JNJ) Pharmaceuticals segment includes immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics.
Analyzing the Performance of Abbott Laboratories in 1Q17
Abbott Laboratories’ stock price rose ~7.1% in 1Q17. On April 7, 2017, the stock’s price had risen 13.7% year-to-date (or YTD).
Recent Developments at Eli Lilly
As discussed earlier, both Eli Lilly’s (LLY) Human Pharmaceuticals and Animal Health segments’ performances were positive in 2016.
How Eli Lilly’s Business Segments Performed in 2016
Eli Lilly’s (LLY) business is classified into two segments: Human Pharmaceuticals and Animal Health.
Bausch & Lomb Continues to be Key Growth Driver for Valeant
Bausch & Lomb projections Valeant Pharmaceuticals expects its Bausch & Lomb/International segment to grow at a CAGR (compound average growth rate) of 4%–6% between 2017 and 2020. In 2017, the company expects the segment to grow 5%–7% after adjusting for foreign exchange fluctuations and the impact of impending patent expiries. In 2017, the segment is also expected […]
New Product Launches May Boost Valeant’s Dermatology Revenue
New product launches Despite upcoming patent expirations for drugs Elidel, Solodyn, and Acanya in 2018, and Zyclara in 2019, Valeant Pharmaceuticals (VRX) expects to boost its dermatology revenue after 2018 through new product launches. On December 12, 2016, the company hired Bill Humpries as executive vice president and head of the dermatology team. The change […]
Relistor May Be Solid Growth Opportunity for Valeant in 2017
Gastrointestinal franchise prescriptions In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) drugs Xifaxan, Uceris, Apris, and Relistor reported solid year-over-year (or YoY) growth in prescriptions, of around 18%, 6%, 4%, and 1%, respectively. Relistor growth trends Since the launch of the oral version of Relistor in 4Q16, the drug has witnessed a 13% rise in total […]
Harvoni: Gilead Sciences’ Blockbuster HCV Drug
Harvoni, a combination drug of ledipasvir 90 mg and sofosbuvir 400 mg, is Gilead Sciences’ (GILD) biggest-selling drug.
How Baxter Continues to Contribute to Patient Care
Baxter has been actively involved in various research and development initiatives to provide better technology products and services to healthcare providers for better patient care.
Gilead Sciences Holds a Broader HIV Portfolio
Gilead Sciences (GILD) holds a share of nearly 80% in the antiretroviral therapy market, which covers ~840,000 patients.
Bristol-Myers Squibb Continues Revenue Growth in 3Q16
Bristol-Myers Squibb (BMY) reported a growth of 21% to $4.9 billion in its 3Q16 results.
Key Investor Insights into Eli Lilly’s Recent Developments
Overall, Eli Lilly’s (LLY) segment-wise performance in 3Q16 was positive for both its Human Pharmaceuticals and Animal Health segments.
Inside Bristol’s Key to Success: Multiple Labels for Opdivo
Opdivo’s significant regulatory advances over the past quarter include approval for head and neck cancer indications, among others.
Understanding Merck’s Business Segments and Their Revenue Trends
Merck & Co. has separated its business operations into two business segments: the Global Human Health business and the Animal Health business.
Baxter International’s Latest Dividend Payment
Baxter International (BAX) announced a quarterly cash dividend of $0.13 per share on July 19, 2016.
Why Generic Drugs Will Play a Key Role in the Future
Although generic drugs are the same as branded drugs in terms of the medicinal effect, their prices are extremely low compared to the branded products.
Analyzing Donald Trump’s Free-Market Healthcare
While Clinton aims to retain and bolster the Affordable Care Act, Trump wants to replace it with a new act that encourages free-market competition.
What’s Driving Growth in Mylan’s Generics Segment?
Mylan’s 2Q16 revenues were mainly driven by 4% growth at constant exchange rates in its Generics segment, which reported a rise to $2.14 billion in 2Q16.
Generics or Specialty: Which Mylan Segment Is Growing Fastest?
Mylan’s (MYL) revenues rose 8% at constant exchange rates in 2Q16, reporting revenues of ~$2.6 billion, as compared to its 2Q15 revenues of ~$2.4 billion.
Population Dynamics for Gilead’s HCV Products
There are six distinct genotypes of HCV (hepatitis C virus). If we know the genotype, recommending the treatment and duration becomes easier.
Digging around to Find Drivers in Danaher’s Environmental Segment
Danaher’s Environmental & Applied Solutions (or, EAS) segment represented 25% of company sales in 2015, or $3.5 billion in value terms.
Pall Acquisition Gave Birth to Danaher’s Filtration Business
Danaher’s filtration business came into existence through the acquisition of Pall in 2015.
How Are Eli Lilly’s Business Segments Performing?
Eli Lilly and Co.’s (LLY) overall business is classified into two business segments—Human Pharmaceuticals and Animal Health.
Akorn’s Robust Research and Development Pipeline: A Growth Driver
Akorn’s (AKRX) robust research and development pipeline is comprised of branded and generic drugs with a total addressable market value of about $9.2 billion.
Franchises that Drove Allergan’s International Sales in 2Q
Allergan’s (AGN) International segment includes the revenues from both branded products and aesthetics products outside the US markets.
Keytruda: Merck’s Immuno-oncology Blockbuster
Keytruda, a prescription medicine classified under Merck and Co.’s (MRK) Immuno-oncology franchise, is used to treat non-small cell lung cancer as well as melanoma.
Bristol-Myers Squibb’s 2Q16 Estimates: Expect Growth!
Bristol-Myers Squibb (BMY) is expected to report revenue growth of over 11% to $4.7 billion in its 2Q16 results on July 28, 2016.
What Lilly Expects for Revenue Growth in 2Q16
Analysts estimate an increase of ~3.4% in Eli Lilly and Company’s (LLY) 2Q16 revenues to reach ~$5.2 billion.
Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst
Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.
How Does Allergan’s Financial Guidance Look for 2016?
Allergan (AGN) estimates that its revenues will be around $17 billion in 2016.
How Did Allergan’s International Brands Segment Perform?
Allergan’s (AGN) international brands segment includes revenues from both branded products and aesthetics products outside the US markets.
How Did Allergan’s Anda Distribution Segment Perform?
Allergan’s (AGN) Anda distribution segment distributes generic pharmaceutical products, vaccines, and over-the-counter products in the US markets.
Why Mylan’s Specialty Segment Reported Strong Q1 Growth
The specialty segment reported an increase of 17% in revenues at $247.9 million in 1Q16 versus $211.1 million in 1Q15.